Cara Total Liab vs Common Stock Total Equity Analysis
CARA Stock | USD 0.64 0.06 8.57% |
Cara Therapeutic financial indicator trend analysis is way more than just evaluating Cara Therapeutic prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cara Therapeutic is a good investment. Please check the relationship between Cara Therapeutic Total Liab and its Common Stock Total Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.
Total Liab vs Common Stock Total Equity
Total Liab vs Common Stock Total Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cara Therapeutic Total Liab account and Common Stock Total Equity. At this time, the significance of the direction appears to have strong relationship.
The correlation between Cara Therapeutic's Total Liab and Common Stock Total Equity is 0.62. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of Cara Therapeutic, assuming nothing else is changed. The correlation between historical values of Cara Therapeutic's Total Liab and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Cara Therapeutic are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Total Liab i.e., Cara Therapeutic's Total Liab and Common Stock Total Equity go up and down completely randomly.
Correlation Coefficient | 0.62 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Most indicators from Cara Therapeutic's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cara Therapeutic current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.The current year's Tax Provision is expected to grow to 0.00, whereas Selling General Administrative is forecasted to decline to about 15.7 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 112.1M | 122.1M | 136.0M | 77.9M | Cost Of Revenue | 1.6M | 7.3M | 6.4M | 6.1M |
Cara Therapeutic fundamental ratios Correlations
Click cells to compare fundamentals
Cara Therapeutic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cara Therapeutic fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 233.0M | 271.2M | 247.1M | 182.2M | 125.8M | 136.4M | |
Other Current Liab | 10.6M | 12.0M | 10.2M | 11.9M | 14.0M | 7.4M | |
Total Current Liabilities | 42.9M | 18.5M | 17.6M | 23.5M | 25.6M | 17.5M | |
Total Stockholder Equity | 186.7M | 249.0M | 227.5M | 158.8M | 57.1M | 112.3M | |
Property Plant And Equipment Net | 3.7M | 5.1M | 3.6M | 2.0M | 8.2M | 8.6M | |
Net Debt | (14.0M) | (26.4M) | (9.8M) | (61.8M) | (9.0M) | (9.5M) | |
Retained Earnings | (400.7M) | (392.3M) | (480.8M) | (566.2M) | (684.7M) | (650.5M) | |
Accounts Payable | 9.1M | 4.9M | 5.6M | 9.6M | 11.6M | 12.2M | |
Cash | 18.3M | 31.7M | 13.5M | 63.7M | 52.2M | 54.8M | |
Non Current Assets Total | 67.3M | 76.1M | 73.8M | 13.3M | 9.7M | 9.2M | |
Cash And Short Term Investments | 155.0M | 180.9M | 167.0M | 145.4M | 101.2M | 104.8M | |
Net Receivables | 1.8M | 2.1M | 1.2M | 4.5M | 4.0M | 4.2M | |
Common Stock Total Equity | 39K | 47K | 50K | 53K | 61.0K | 33.2K | |
Common Stock Shares Outstanding | 42.7M | 47.9M | 50.7M | 53.7M | 54.1M | 35.8M | |
Short Term Investments | 136.7M | 149.2M | 153.6M | 81.7M | 49.0M | 93.8M | |
Liabilities And Stockholders Equity | 233.0M | 271.2M | 247.1M | 182.2M | 125.8M | 136.4M | |
Non Current Liabilities Total | 3.4M | 3.7M | 1.9M | 11.5M | 43.2M | 45.3M | |
Other Current Assets | 9.7M | 13.6M | 2.5M | 16.7M | 8.2M | 5.4M | |
Other Stockholder Equity | 587.2M | 641.2M | 708.6M | 726.6M | 742.0M | 395.3M | |
Total Liab | 46.2M | 22.2M | 19.5M | 23.5M | 68.8M | 72.2M | |
Property Plant And Equipment Gross | 3.7M | 5.1M | 3.6M | 2.0M | 9.9M | 10.3M | |
Total Current Assets | 165.7M | 195.1M | 173.3M | 168.9M | 116.2M | 112.2M | |
Accumulated Other Comprehensive Income | 170K | 73K | (358K) | (1.7M) | (260K) | (273K) | |
Common Stock | 39K | 47K | 50K | 53K | 54K | 35.2K | |
Property Plant Equipment | 700K | 840K | 631K | 426K | 383.4K | 364.2K | |
Net Tangible Assets | 190.1M | 252.7M | 229.4M | 158.8M | 182.6M | 155.7M | |
Retained Earnings Total Equity | (400.7M) | (392.3M) | (480.8M) | (566.2M) | (509.6M) | (484.1M) | |
Capital Surpluse | 587.2M | 641.2M | 708.6M | 726.6M | 835.6M | 525.5M | |
Net Invested Capital | 186.7M | 249.0M | 227.5M | 158.8M | 57.1M | 54.2M | |
Net Working Capital | 122.8M | 176.6M | 155.7M | 145.5M | 90.6M | 142.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Cara Stock
When determining whether Cara Therapeutic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cara Therapeutic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cara Therapeutic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cara Therapeutic Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.26) | Revenue Per Share 0.312 | Quarterly Revenue Growth (0.65) | Return On Assets (0.62) | Return On Equity (1.47) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.